As psychedelic research expands, so does the promise of applications across a wide variety of mental health conditions. Approximately one in eight people in the US is diagnosed with postpartum depression, but only one in four exhibiting symptoms received a perinatal mood and anxiety disorder diagnosis, and only half reported receiving mental health care in the first year postpartum. Alternative treatments like psychedelic therapy have not been studied in this population, in part due to the ethical complexities.

Reunion Neuroscience, a biopharmaceutical company, recently released Phase 2 clinical data on RE104, its proprietary psilocybin-like compound, demonstrating a statistically significant reduction in depression scores sustained through a 28-day follow-up. Preliminary findings from a separate lactation study also suggest that breastfeeding or chestfeeding can be safely resumed shortly after treatment with RE104. Lactation studies and studies on birthing parents specifically are exceedingly rare in psychedelics; these results have promising potential for the future of research in this area.

Plant Parenthood will host a webinar with Dr. Camille Hoffman, a site Principal Investigator on Reunion’s trials, to discuss the results of the Phase 2 study, the lactation study and what Reunion hopes to discover about the impact of its psilocybin compound in the future. We will also discuss the broader implications of this research on post partum health and lactating parents.

We will include time for participant Q&A.

This webinar will be recorded and sent to all ticket holders who cannot attend live.